Ipsen is a biopharmaceutical company focused on specialty care medicines in oncology, rare diseases and neuroscience. Its portfolio includes targeted therapies and other specialty drugs developed and commercialized for patients with high unmet medical need. The group combines internal R&D with partnerships and operates primarily in Europe, North America and selected international markets.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 3,156.5 | — | 648.6 | — |
| 2023 | 3,306.4 | 4.8% | 644.4 | -0.7% |
| 2024 | 3,574.5 | 8.1% | 345.9 | -46.3% |
| 2025 | 3,929.2 | 9.9% | 443.5 | 28.2% |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: Eurofins Scientific SE (ERF), Bureau Veritas SA (BVI), Carrefour SA (CA), Klépierre SA (LI), Bolloré SE (BOL), Aeroports de Paris SA (ADP)